Satsuma Pharmaceuticals Inc

Satsuma Pharmaceuticals — Investor Presentation (December 2022)

78 slides from Satsuma Pharmaceuticals's investor presentation, Dec 20, 2022

  1. Slide 1: STS101 program and corporate overview

    pharmaceuticals STS101 program and corporate overview NASDAQ: STSA | December 20, 2022

  2. Slide 2: Corporate summary and STS101 program overview

    Satsuma Pharmaceuticals corporate summary and STS101 program overview 2

  3. Slide 3: Satsuma Pharmaceuticals (Nasdaq: STSA)

    Satsuma Pharmaceuticals (Nasdaq: STSA) Focus • Developing STS101 (DHE nasal powder) for the acute treatment of migraine o Differentiated, NDA-stage asset with low regulatory risk and significant commercial potential Financial • Cash and equivalents as of October 31, 2022: $59.4M • Basic shares outst

  4. Slide 4: STS101: dihydroergotamine (DHE) nasal powder

    STS101: dihydroergotamine (DHE) nasal powder Differentiated, NDA-stage asset with fast, low-cost / low-risk path to FDA approval and significant commercial potential • Indication: acute treatment of migraine with or without aura in adults • Large clinical trial program: >1,600 subjects who treated >

  5. Slide 5: STS101 is the first and only DHE product with potential for broad utilization

    STS101 is the first and only DHE product with potential for broad utilization TRUSTED AND POWERFUL Active, dihydroergotamine (DHE) has long been considered a gold-standard treatment for migraine PROVEN EFFICACY IN SUMMIT PH3 TRIAL Robust and long-lasting efficacy through 48h with single dose Numeric

  6. Slide 6: Available DHE products are not easy-to-use, well-tolerated or consistently effective

    Available DHE products are not easy-to-use, well-tolerated or consistently effective DHE forInjection DHE liquid nasal sprays (IV, IM, SC) sprays Marketed since 1946 MIGRANAL: approved in 1997 Trudhesa: approved 2021 Highly variablePK results in unreliable clinical Considered gold standard treatment

  7. Slide 7: STS101 PK profile is optimized to maximize efficacy while minimizing side effects

    STS101 PK profile is optimized to maximize efficacy while minimizing side effects Establishes PK bridge to listed products (MIGRANAL and DHE for injection) required for 505(b)(2) pathway approval Rapidly achieves and sustains target drug plasma concentrations that maximize efficacy while minimizing

  8. Slide 8: Intuitive simple administration – a full dose within seconds

    Intuitive simple administration –a full dose within seconds 1 2 3 FOLD OFF TAB INSERT IN ONE NOSTRIL SQUEEZE TO DELIVER 8

  9. Slide 9: SUMMIT Phase 3 efficacy trial summary

    SUMMIT Phase 3 efficacy trial summary (1,424 subjects in mITTpopulation) • Randomized, double-blind, controlled trial comparing STS101 5.2 mg (single dose) and placebo • STS101 (single dose) demonstrated robust and sustained anti-migraine efficacy, but did not achieve statistical significance on pre

  10. Slide 10: STS101 is a differentiated and best-in-class DHE product

    STS101 is a differentiated and best-in-class DHE product We believe STS101 availability will drive broader utilization of DHE Key attributes STS101 MIGRANAL & DHE for injection Robust efficacy demonstrated in Yes No No placebo-controlled trials? Favorable safety and tolerability Yes No No profile, w

  11. Slide 11: Market dynamics for Rx migraine treatments are favorable

    Market dynamics for Rx migraine treatments are favorable Today Future Total acute treatment market is Favorable long-term dynamics: comprised of both Migraine-specific Market for migraine-specific treatments is large, growing and Nonspecific treatments and has significant long-term growth potential

  12. Slide 12: Acute treatment of migraine market is large and has considerable room to grow

    Acute treatment of migraine market is large and has considerable room to grow STS101 is well-positioned to capture significant market share 1 Large number of patients are 2 Physicians and patients are highly interested in STS101 candidates for treatment with • Physicians see STS101 has having broad

  13. Slide 13: Acute migraine market is large and rapidly growing

    The acute treatment of migraine market is large and rapidly growing, with a relatively small group of high prescribers driving growth U.S. Prescriptions for Migraine-Specific Acute Treaments1 Commercial success of new migraine products underscores large market opportunity, significant unmet 2021 US

  14. Slide 14: STS101 program overview

    STS101 program overview STS101 All clinical trials necessary for Late-stage asset with significant Acute treatment of migraine (DHE nasal powder) NDA filing are complete commercial potential Large and growing multi-billion We believe STS101 is approvable, First and only DHE product suitable dollar m

  15. Slide 15: DHE for injection is viewed by HCPs as highly effective

    Dihydroergotamine (DHE) for injection is viewed by HCPs as highly effective DHE for injection Clinical attribute Triptans DHE • First approved in 1946 Long treatment window with minimal attenuation of effect when administered late in • Long recommended as a first-line option for course of attack1 ×

  16. Slide 16: STS101 (DHE nasal powder) is unique, highly innovative

    STS101 (DHE nasal powder) is unique, highly innovative and designed to meet the needs of people with migraine Proprietary, advanced dry-powder formulation technology and single-use nasal delivery device Simple MucoAdhesiveRelease Technology (SMART) combines mucoadhesive drug carrier and engineered d

  17. Slide 17: How STS101 DHE nasal powder works

    How STS101 DHE nasal powder works 1 Creates a steep drug concentration DHE gradient across nasal membrane that drives rapid absorption DRUG CARRIER Mucoadhesive particles adhere to 2 nasal mucosa, providing sustained delivery of DHE over time Not feasible with liquid DHE 3 formulations due to poor s

  18. Slide 18: How STS101 DHE nasal powder works: nasal anatomy

    How STS101 DHE nasal powder works Human nasal anatomy STS101 formulation engineered to 1 maximize deposition on surface of respiratory mucosa (97% of nasal mucosal surface) STS101 target tissue 2 Less drug run off/loss out of nose and down throat vs liquid nasal sprays Respiratory mucosa • 5x more v

  19. Slide 19: STS101 is the first and only DHE product suitable for broad use

    STS101 is the first and only DHE product suitable for broad use • STS101 has key differentiating features long desired by physicians in a DHE product: ✓Proven robust and long-lasting efficacy with single dose ✓Quick and easy self-administration ✓Favorable safety and tolerability, with low rates of l

  20. Slide 20: Market for acute treatment of migraine therapies and STS101 commercial opportunity

    Market for acute treatment of migraine therapies and STS101 commercial opportunity 20

  21. Slide 21: Growing market with concentrated high-prescriber audience

    Growing market with concentrated high-prescriber audience ~15k physicians prescribe ~40% of all migraine-specific acute treatments Est. 2024 Rx’s for Large pharma DTC promotion and disease awareness initiatives will continue to migraine-specific focus on building and expanding market treatments Pfiz

  22. Slide 22: STS101 is uniquely positioned for broad use

    STS101 is uniquely positioned for broad use STS101 overcomes deficiencies of STS101 in the migraine treatment paradigm injectable and liquid nasal spray Significant CV disease DHE products, enabling broader or risk factors? utilization of DHE ? Triptan No Yes Gepant or Inadequate response ? or poor

  23. Slide 23: Pricing of newer branded and DHE liquid nasal spray products

    Pricing of newer branded and DHE liquid nasal spray products indicated for the acute treatment of migraine Product WAC per dose Note that price / dose does not necessarily reflect cost of a treating an attack, as multiple doses of a Newer oral branded products product are frequently required and uti

  24. Slide 24: Satsuma primary market research points to large commercial opportunity

    Previous Satsuma primary market research conducted with HCPs, patients and payers* points to large STS101 commercial opportunity Satsuma primary market research summary* HCPs (qualitative and quantitative, including survey results from ~700 physicians) 70% of surveyed physicians expressed high inter

  25. Slide 25: STS101 commercial opportunity and positioning

    STS101 commercial opportunity and positioning STS101 is an appropriate and evidence-based treatment for a wide variety of patients and attack types: Insufficient responders to triptans and/or gepants • 20-40% of patients do not achieve adequate relief with current treatments • Prescription discontin

  26. Slide 26: STS101 commercial opportunity and positioning: additional patient types

    STS101 commercial opportunity and positioning Headache specialists view STS101 as having further utility in additional patient and attack types Medication Overuse Headache • ~1-2% population prevalence • DHE administered by injection is commonly used to treat Medication Overuse Headache Patients req

  27. Slide 27: STS101 brand development

    STS101 brand development Activities completed • STS101 tradename established Conditionally approved by FDA Tested with HCPs Trademark application filed Web domains secured • Branding Brand positioning, personality, character and hallmark work, including logo and colors, completed 27

  28. Slide 28: STS101 clinical development

    STS101 clinical development 28

  29. Slide 29: STS101 clinical trial program

    STS101 clinical trial program Required by FDA to support ST101 clinical trials Trial Objective NDA filing and approval? Key clinical trials conducted with investigational product incorporating to-be-marketed nasal delivery device Phase 1 PK trial STS101-006 Establish PK bridge to listed products Yes

  30. Slide 30: Phase 1 PK trial STS101-006

    Phase 1 PK trial STUDY STS101-006 Objective: Establish PK bridge to listed products, MIGRANAL and D.H.E. 45 Required by FDA to support STS101 NDA and potential approval via 505(b)(2) regulatory pathway Investigational product incorporates to-be-marketed nasal delivery device 30

  31. Slide 31: STS101 5.2 mg achieved target PK profile in 2021 Ph1 trial

    STS101 5.2 mg achieved target PK profile in 2021 Ph1 trial (STS101-006) PK profile optimized to maximize efficacy while minimizing sideeffects 2021 Ph1 PK study with 2nd generation delivery device Established PK bridge to listed products (MIGRANAL and D.H.E. 45) required for 505(b)(2) pathway Mean D

  32. Slide 32: ASCEND Phase 3 open-label, long-term safety trial

    ASCEND Phase 3 open-label, long-term safety trial STUDY STS101-003 Objective: Characterize local nasal toxicity profile of STS101 Required by FDA to support STS101 NDA and potential approval via 505(b)(2) regulatory pathway Study initiated in August 2020 with STS101 incorporating 1st-generation devi

  33. Slide 33: ASCEND long-term, open-label safety trial objectives and design

    ASCEND long-term, open-label safety trial objectives and design (Study STS101-003) • PRIMARY OBJECTIVES:—Assess safety and tolerability of STS101 5.2 mg over 6 and 12 months—Satisfy FDA requirement to characterize local nasal toxicity of STS101 in ≥150 subjects who treat ≥2 migraine attacks/month fo

  34. Slide 34: ASCEND is one of the largest-ever trials conducted with a DHE product

    ASCEND is one of the largest-ever trials conducted with a DHE product 482 subjects enrolled, with 446 subjects using ≥10,000 doses of STS101 to treat ≥8,000 attacks for up to ~18 months—~19% of subjects discontinued by Satsuma due to insufficient number of attacks—~100 active subjects in trial as of

  35. Slide 35: STS101Mk2 demonstrates favorable safety and tolerability profile

    STS101Mk2 demonstrates favorable safety and tolerability profile • No clinically relevant systemic safety findings (vital signs, EKGs, labs), or local nasal tolerability or safety findings • AEs were typically mild (82.7%) and transient • Low rates of treatment-related nausea and vomiting • Only 4.1

  36. Slide 36: STS101Mk2 demonstrated robust efficacy despite high rates of poor-response symptoms

    STS101Mk2 demonstrated robust efficacy despite treated attacks having high rates of symptoms predictive of poor response Among the 172 subjects who used STS101Mk2 exclusively to treat their attacks: Exploratory efficacy endpoints % of all treated Treated attacks had high rates of attacks (n=1,932) s

  37. Slide 37: % of attacks in which Pain Freedom achieved

    % of attacks in which Pain Freedom achieved (among 172 subjects who exclusively used STS101MK2 to treat 1,932 attacks) Pain freedom over time (%) 86 87 65 34 12 1 HR 2 HR 4 HR 24 HR 48 HR Source: STS101-003 NDA Interim Analysis June 30, 2022; Expansion cohort only: 172 subjects with data from 1932 t

  38. Slide 38: % of attacks in which freedom from MBS achieved

    % of attacks in which freedom from MBS achieved (among 172 subjects who exclusively used STS101MK2 to treat 1,932 attacks) Most bothersome symptom freedom over time (%) 91 90 79 53 27 1 HR 2 HR 4 HR 24 HR 48 HR Source: STS101-003 NDA Interim Analysis June 30, 2022; Expansion cohort only: 172 subject

  39. Slide 39: Low use of rescue medication and allowed 2nd STS101 dose

    Low use of rescue medication and allowed 2nd STS101 dose in most attacks (among 172 subjects who exclusively used STS101MK2 to treat 1,932 attacks) Parameter 24 hrs 48 hrs % Attacks % Attacks Use of rescue medication 3.9 5.4 Second dose of STS101 18.5 18.6 Source: STS101-003 NDA Interim Analysis Jun

  40. Slide 40: ASCEND subjects reported consistently favorable impressions of STS101

    ASCEND subjects reported consistently favorable impressions of STS101 and its antimigraine effects over time Subject impressions of STS101 after 3, 6 & 12 months of use 40 n=289-290 at month 3; 220 at month 6; 122 at month 12

  41. Slide 41: ASCEND subjects reported favorable impressions of antimigraine effects

    ASCEND subjects reported consistently favorable impressions of STS101 and its antimigraine effects over time Subject impressions of STS101 antimigraine effects after 3, 6 & 12 months of use 41 n=283-284 at month 3; 216 at month 6; 120-121 at month 12

  42. Slide 42: SUMMIT Phase 3 double-blind, placebo-controlled, efficacy trial

    SUMMIT Phase 3 double-blind, placebo-controlled, efficacy trial STUDY STS101-007 Objective: Establish product-specific efficacy results for inclusion in Section 14 of prescribing information NOT required by FDA to support STS101 NDA and potential approval via 505(b)(2) regulatory pathway Investigati

  43. Slide 43: SUMMIT is the largest-ever trial of any DHE product

    SUMMIT is the largest-ever trial of any DHE product and was conducted in accordance with current migraine trial design, data analysis and quality standards Screening Randomization & treatment End-of-study visit up to 30 days 56 days Within 10 days of treatment 1:1 randomization STS101 5.2 mg* R End-

  44. Slide 44: Endpoint definitions

    Endpoint definitions Pain Freedom and Pain Relief Patients report pain severity in electronic diary on a 4-point scale 0 1 2 3 No Pain Mild Pain Moderate Pain Severe Pain SUMMIT subjects treated migraine attacks with Moderate or Severe Pain (i.e., rated as a “2” or “3”) immediately prior to treatmen

  45. Slide 45: Subject disposition

    Subject disposition STS101 Placebo Randomized 796 795 Modified Intent-to-Treat* 716 708 Safety** 731 729 *Subject treated qualifying migraine attack with study medication and has at least 1 post-treatment diary entry **Subject used study medication 45

  46. Slide 46: Subject demographics & migraine history

    Subject demographics & migraine history (mITT population) Subjects’ demographics and migraine history were representative of typical migraine patient population STS101 Placebo Age (mean; SD) 38.2 yrs (11.4) 38.9 yrs (11.5) Gender (% M/F) 21/79 20/80 Race (%) White 82.5 81.4 African American 12 13.7

  47. Slide 47: Characteristics of treated migraine attacks

    Characteristics of treated migraine attacks (mITT population) High proportion of SUMMIT subjects had pre-treatment attack characteristics indicative of difficult-to-treat and long-duration attacks that are poorly responsive to treatment Symptoms just before treatment STS101 Placebo (% of subjects wi

  48. Slide 48: STS101 numerically superior to placebo at 2h on co-primary endpoints

    STS101 was numerically superior to, but not statistically different than placebo at 2h post-treatment on co-primary endpoints STS101 Placebo STS101 Placebo (n=716) (n=708) Difference p-value (n=701) (n=699) Difference p-value 20.4% 17.5% 2.9% 0.1661 37.8% 32.9% 4.9% 0.0552 1. MBS: Most-bothersome sy

  49. Slide 49: STS101 demonstrated sustained effects on Pain Freedom and Freedom from MBS

    STS101 (single dose) demonstrated sustained effects on Pain Freedom and Freedom from MBS endpoints • STS101 (single dose) demonstrated robust and sustained anti-migraine efficacy, but did not achieve statistical significance on pre-specified co-primary endpoints of % Free from Pain and % Free from M

  50. Slide 50: SUMMIT Phase 3 secondary endpoint summary

    SUMMIT Phase 3 efficacy trial secondary endpoint summary ✓STS101 demonstrated robust and sustained anti-migraine effects across key secondary endpoints, including those considered clinically relevant and recommended for assessment in efficacy trials by the FDA and/or IHS guidelines* IHS guidelines?

  51. Slide 51: STS101 relieved migraine pain and enabled Total Migraine Freedom

    STS101 (single dose) relieved migraine pain and enabled subjects to achieve Total Migraine Freedom • Pain relief—Numerical separation vs placebo by 1.5h post-treatment—Statistically significant (p=0.0017) at 2h post-treatment and at all subsequent timepoints through 48h • TOTAL MIGRAINE FREEDOM = Fr

  52. Slide 52: STS101 showed effects in difficult-to-treat attacks

    STS101 showed effects in difficult-to-treat attacks* • Attacks with allodynia—Lipton et al., Headache 2017: “Because personswithallodynia were likely to have inadequate responses across a range of medications (triptans, NSAIDs, opioids, barbiturates, ergots) there is an unmet need for treatment of p

  53. Slide 53: STS101 exhibited favorable safety and tolerability profile

    STS101 exhibited favorable safety and tolerability profile • Consistent with previous STS101 Placebo clinical trial results, STS101 showed favorable safety & Safety Population (n) 731 729 tolerability profile Treatment-Emergent Adverse Events reported by >1% of subjects • Low incidence of nausea Nas

  54. Slide 54: SUMMIT trial results in comparison with other DHE products and gepants

    SUMMIT trial results in comparison with other DHE products and gepants 54

  55. Slide 55: STS101 efficacy in SUMMIT compares favorably with approved DHE products

    STS101 efficacy in SUMMIT trial compares favorably with efficacy of approved DHE products STS101 Endpoint MIGRANAL TRUDHESA D.H.E. 45 SUMMIT trial Pivotal Statistically significant vs placebo? study 2h 4h 1 ✓ FDA finding of * ✓* effectiveness not Pain relief ✓ 2h* -48h* 2 ✗ ✓* supported by No prod

  56. Slide 56: STS101 safety and tolerability compare favorably with approved DHE products

    STS101 safety and tolerability compare favorably with approved DHE products STS101 DHE Treatment-emergent AE rates DHE injection SUMMIT / ASCEND trials liquid nasal sprays ~16%(SC) Nausea 1.9% / 4.9% 10% Est. >50% (IV) Vomiting 0.8% / 1.7% 4% ~7% (SC) TRUDHESA: 52.3% Local (nasal) irritative adverse

  57. Slide 57: Treated attacks in SUMMIT had higher rates of baseline symptoms than gepant trials

    As compared with gepantPh3 trials, treated attacks in SUMMIT trial had higher rates of baseline symptoms predictive of poor response to treatment Not reported for gepanttrials Reported at screening visit Source: NurtecSBA, UbrelySBA, Lipton et al., JAMA 2019 57

  58. Slide 58: STS101 absolute response rates from 0-2h similar to gepants

    STS101 achieved absolute Pain-free and MBS-free response rates from 0-2h similar to gepants • Comparison of absolute response rates 0-2h for STS101 / SUMMIT Gepant / Ph3 trials STS101 (SUMMIT), NURTEC and UBRELVY (PI) Pain Free at 2h -Active 20.4% 19.2% – 21.8% Placebo 17.5% 11.8% -14.3% • Gepant tr

  59. Slide 59: STS101 demonstrated high absolute response rates for all symptoms

    STS101 demonstrated high absolute response rates for all symptoms despite treated attacks having high rates of baseline symptoms predictive of poor response 59

  60. Slide 60: Regulatory

    @atsuma pharmaceuticals ! Regulatory

  61. Slide 61: STS101 and the 505(b)(2) pathway

    STS101 and the 505(b)(2) pathway STS101 505(b)(2) strategy relies partially on referenced information, including: • Nonclinical toxicology data (long-term tox, reproductive tox, carcinogenicity studies) • Pharmacology data, including clinical pharmacology study results • Thorough QT study results •

  62. Slide 62: Regulatory strategy, status and timelines

    Regulatory strategy, status and timelines Straightforward and precedented path to regulatory approval via 505(b)(2) pathway based on FDA feedback from May 2022 Type B pre-NDA clinical and CMC meetings and two previous Type C meetings ✓FDA agrees that requisite 505(b)(2) scientific bridge to listed p

  63. Slide 63: Confident STS101 regulatory strategy will support NDA filing and approval

    Based on input from our expert legal-regulatory consultants, we are confident our STS101 regulatory strategy will support NDA filing and potential approval • Satsuma’s longstanding STS101 regulatory strategy has been to seek FDA approval via the 505(b)(2) pathway • In three meetings, including May 2

  64. Slide 64: Strong case for including SUMMIT efficacy results in the STS101 label

    Based on input from expert legal-regulatory consultants, we believe there is a strong case for including SUMMIT trial efficacy results in the STS101 label Arguments for including SUMMIT efficacy trial results in the MIGRANAL (approved 1997) D.H.E. 45 STS101 label SUMMIT is a large, placebo-controlle

  65. Slide 65: CMC

    @atsuma pharmaceuticals

  66. Slide 66: CMC summary

    CMC summary Commercial supply chain and commercial-scale manufacturing capability established • Formulation manufacture by world-class CMO • Manufacture of nasal delivery device components (Satsuma owns commercial mold tooling) • Filling, assembly and packaging. (Satsuma owns custom, high-speed, aut

  67. Slide 67: Intellectual property and barriers to competitive entry

    Intellectual property and barriers to competitive entry 67

  68. Slide 68: Significant long-term barriers to competitive entry / generics

    Significant long-term barriers to competitive entry / generics Broad IP estate, with >60 issued and pending patents, reflects innovative nature of STS101 and our drug delivery technologies • Patentscover formulations, dosages, devices, and methods of treatment • 10 issued U.S. patents with estimated

  69. Slide 69: Competition

    @atsuma pharmaceuticals ! Competition

  70. Slide 70: Impel Pharmaceuticals' Trudhesa (INP104) DHE liquid nasal spray

    Impel Pharmaceuticals’ Trudhesa (INP104) DHE liquid nasal spray • Dosage form (liquid solution) and container closure system (vial) identical to MIGRANAL, only difference vs MIGRANAL is nasal delivery device • TRUDHESA nasal delivery device is HFA propellant-powered, single-dose POD device, that Imp

  71. Slide 71: TRUDHESA / INP104 delivered with propellant-powered device

    TRUDHESA / INP104: MIGRANAL DHE liquid nasal spray-–delivered with propellant-powered device rather than manual spray pump Nasal Spray Device Parts FDA review: “The I123 POD device is designed to apply DHE higher in the nasal cavity than typical nasal spray devices (although any clinical advantages

  72. Slide 72: INP104 PK is similar to MIGRANAL and much lower than STS101

    INP104 PK is similar to MIGRANAL and much lower than STS101 • Whether INP104 exposure is sufficient for robust 2h efficacy is uncertain • Comparative Migranal Cmax and PK PK results from same trial results reported by Impel in INP104 Ph1 PK trial are lowest ever reported for Migranal and much lower

  73. Slide 73: INP104 has higher PK variability than STS101 and MAP0004

    INP104 has higher PK variability than STS101 and MAP0004* Similar to MIGRANAL, INP104 exhibits higher PK variability vs STS101 and MAP0004 73 *MAP0004 is unapproved, discontinued oral pulmonary-route DHE product that demonstrated positive results in large Ph3 trial

  74. Slide 74: Trudhesa prescription data to date suggest slow uptake

    Trudhesa prescription data to date suggest slow uptake Underlying reasons for slow uptake • Inferior product: poor ease-of-use; large size; complex multi-step administration procedure; messy: drips out ofnose and runs down back of throat • Product may not perform as advertised: poor and inconsistent

  75. Slide 75: Additional non-oral route, late-stage products

    Additional non-oral route, late-stage products Competitor Status Comments AMNEAL Pharmaceuticals • NDA filed Q2 2021 • DHE for injection + autoinjector device DHE auto-injector • AMNEAL currently projecting • AMNEAL projects $0.5B addressable market potential launch in 2024 opportunity and $50-100M

  76. Slide 76: Thank you

    @atsuma pharmaceuticals Thank you aH

  77. Slide 77: Satsuma & Shin Nippon Biomedical Laboratories, Ltd.

    Satsuma & Shin Nippon Biomedical Laboratories, Ltd. • Established 1957 • Traded on Tokyo Exchange (Securities code: 2395) • >2,000 employees • Core businesses include preclinical / toxicology and clinical research services (in JV with PPD) • Strong history of innovation 2012 Established WAVE Life Sc

  78. Slide 78: MAP Pharmaceuticals / MAP0004 recap

    MAP Pharmaceuticals / MAP0004 recap Pulmonary-route DHE product developed by MAP Pharmaceuticals 28% Pain Free @2h vs 10% for placebo Complex & novel product with MAP0004 & STS101 5.2 mg have similar early PK Robust efficacy in large RCT (FREEDOM) manufacturing challenges & Cmax Sources: Allergan Gl

Satsuma Pharmaceuticals — Investor Presentation (December 2022) on 6ix